A61K9/5021

Methods of fabricating hyper compliant polymer particles and methods of use and compositions

Compositions and methods are provided for making hyper compliant polymer particles by inverse emulsification and having a predetermined mechanical compliance and a predetermined size with a monodisperse diameter. Compositions and methods are provided for use of hyper compliant polymer particles in drug delivery, assay, particle image velocimetry, ceramics, cosmetics, deconvolution, electronic paper, insulation, personal care, standards, retroreflective paint and paint applications, thickening agents, regenerative medicine, device calibration, micro-carriers and force indicators.

METHODS FOR PROMOTING ANTI-TUMOR IMMUNE RESPONSE IN A SUBJECT IN NEED THEREOF USING ENCAPSULATED INTERLEUKIN 12

The present invention relates to methods for promoting anti-tumor immune response in a subject in need thereof using encapsulated interleukin 12 (IL-12).

THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY

A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USE

A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.

COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
20220211641 · 2022-07-07 ·

Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

Microparticles
11273207 · 2022-03-15 · ·

The invention provides a blood substitute product comprising haemoglobin and a self-assembled microparticle having an acid having two or more acid groups and an organic base in a solvent. The particle is of micron scale. The microparticle may be obtained by contacting a bis-acid and organic base in a hydrophilic solvent, wherein the acid is insoluble or sparingly soluble in the hydrophilic solvent and the organic base is soluble in a hydrophilic solvent.

Bioerodible implant for long-term drug delivery and associated methods of manufacture and use

A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.

NEW DELIVERY SYSTEM
20210177766 · 2021-06-17 ·

The present invention relates to a new delivery system for nutritional ingredients (nutraceuticals). These nutritional ingredients are useful for gut and metabolic health in monogastric animals, especially in humans.

MOISTURE RESISTANT PROBIOTIC GRANULE AND METHODS OF PRODUCING THE SAME
20210186887 · 2021-06-24 ·

There is provided a probiotic microcapsule comprising a core comprising probiotic microorganisms; and a coating layer comprising a hybrid solid dispersion comprising an edible fatty molecule evenly dispersed within a water-soluble film forming polymer and an edible mediator, wherein said edible mediator is starch octenyl succinate.

MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES
20210162055 · 2021-06-03 ·

An aqueous liquid suspension containing a coated drug—ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine—ion exchange resin complex is provided. The coated amphetamine—ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.